Skip to main content
. 2020 Aug 27;18:323. doi: 10.1186/s12967-020-02493-8

Fig. 1.

Fig. 1

Representative bioanalyzer images of freshly isolated cfDNA from women with cancer (ac) with contaminating high molecular weight DNA (marked with a black arrow and dotted line), the fraction of DNA from the same patients removed after the 0.5× SPRI AMPure bead purification step (d–f), and the resulting purified LMW cfDNA recovered after the 1.6× dilution SPRI AMPure bead purification (gi). The desired cfDNA peak is marked with a green arrow and dotted line